Day: October 27, 2021

All amounts are in USD unless stated otherwiseiGMIN has acquired the construction ready Tocantinzinho Gold Project in Brazil for $115 millionii Tocantinzinho is a permitted, high-grade gold project with a 10-year reserve life with an estimated annual production of 187,000 ounces for the first 8 yearsiii Leadership team to leverage four successful mine builds in South America, including recently for Newmont Corporation (Merian) and Lundin Gold Inc. (Fruta del Norte) GMIN completed a C$71 million ($56 million) equity financing Post closing, GMIN estimates its cash balance to be approximately $66 million GMIN is building a new intermediate gold producer; Tocantinzinho is Step 1BROSSARD, Québec, Oct. 27, 2021 (GLOBE NEWSWIRE) — G Mining Ventures Corp. (“GMIN” or the “Corporation”) is pleased to announce that it has completed its...

VANCOUVER, British Columbia, Oct. 27, 2021 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (“Eldorado” or “the Company”) announces that it has closed the previously announced sale of the Tocantinzinho Project (“TZ”) to G Mining Ventures Corp. (“GMIN”). As part of closing, Eldorado and GMIN have entered into an investor rights agreement (“Investor Rights Agreement”), which grants Eldorado certain rights for so long as it maintains 10% ownership of GMIN common shares on an undiluted basis. The Investor Rights Agreement includes:A customary lockup period until the earlier of (i) two years, and (ii) GMIN making a positive construction decision on TZ. The right for Eldorado to participate in future equity offerings by GMIN in order to maintain the greater of 19.9% of GMIN’s share capital and Eldorado’s pro rata ownership interest prior...

Agreement Provides for Option to License Alzheimer’s Therapeutic Englewood Cliffs NJ, Oct. 27, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has entered into a sponsored research agreement with Columbia University pursuant to which Silo has been granted an option to license certain assets currently under development, including Alzheimer’s disease. This agreement incorporates the work of Dr. Christine Ann Denny, an Associate Professor of Clinical Neurobiology (in Psychiatry) at Columbia University Irving Medical Center. Denny and her team are focusing their efforts on the molecular mechanisms underlying learning and memory, including diseases such as Alzheimer’s disease. An estimated 5.8 million...

VANCOUVER, British Columbia, Oct. 27, 2021 (GLOBE NEWSWIRE) — Macarthur Minerals Limited (ASX: MIO) (TSX-V: MMS) (OTCQB: MMSDF) (the Company or Macarthur) is holding its 2021 Annual General Meeting today. Attached is a copy of the Chairman’s address. On behalf of the Board of Directors, Mr Cameron McCall, Chairman For more information please contact:Joe Phillips  Managing Director  +61 7 3221 1796  communications@macarthurminerals.com      Investor Relations – Australia Investor Relations – CanadaAdvisir Investor CubedAlex Bunney, Manager Client Services Neil Simon, CEOalex.bunney@advisir.com.au  +1 647 258 3310  info@investor3.ca Company profileMacarthur is an iron ore development, gold and lithium exploration company that is focused on bringing to production its Western Australia iron ore...

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, November 3, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.Conference call and webcast:Date: November 3, 2021Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)Dial-in: (855) 779-9066 (Domestic) or (631) 485-4859...

WILMETTE, Ill., Oct. 27, 2021 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that the first patient has been dosed in its open-label dose-escalation Phase 1b clinical trial evaluating camsirubicin for the treatment of advanced soft tissue sarcoma (ASTS). “We are very pleased to have dosed our first patient so quickly after trial initiation and so soon following our FDA allowance to proceed in early August. The strong interest and support we are seeing within the oncology community for this study adds to our hopeful excitement and anticipation of the potential impact that escalating doses of camsirubicin may have on improving patient outcomes,”...

VANCOUVER, British Columbia, Oct. 27, 2021 (GLOBE NEWSWIRE) — Macarthur Minerals Limited (ASX: MIO) (TSX-V: MMS) (OTCQB: MMSDF) (the Company or Macarthur) is pleased to announce that all resolutions were passed at the Annual General Meeting of the Company held today in Brisbane, Australia. Resolution 10, Approval of 10% Placement Facility was a Special Resolution which passed with the requisite 75% majority. The results in respect of each of the resolution put to shareholders at the Annual General Meeting are set out in Appendix 1. On behalf of the Board of Directors, Mr Cameron McCall, ChairmanFor more information please contact:   Joe PhillipsManaging Director+61 7 3221 1796communications@macarthurminerals.com     Investor Relations – AustraliaAdvisirAlex Bunney, Manager Client Servicesalex.bunney@advisir.com.au Investor...

MANITOWOC, Wis., Oct. 27, 2021 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, controls and IoT systems, including turnkey project implementation, program management and system maintenance, will host a conference call and webcast to review its fiscal 2022 second quarter results on Tuesday, November 9, 2021, at 10:00 a.m. ET / 9:00 a.m. CT. Orion plans to release its results prior to the market open that morning.Webcast/Call DetailsDate / Time:          Tuesday, November 9th at 10:00 a.m. ETCall Dial-In:   Dial (877) 754-5294 or (678) 894-3013 for internationalWebcast / Replay:   https://edge.media-server.com/mmc/p/scxrpqtxAudio Replay:   (855) 859-2056, ID#3529289 (available shortly after call through 11/16/21)     About Orion Energy...

Harvia Plc press release 27 October 2021 at 3:00 P.M. EETHarvia will publish its Interim Report for the period of January−September 2021 on Thursday, 4 November 2021 at around 09:00 a.m. Finnish time. The stock exchange release and the presentation material will be available after publishing at https://harviagroup.com/investor-relations/. Harvia will hold a webcast for analysts, investors and media on 4 November 2021 at 11:00 a.m. EET. The conference will be held in English. Harvia’s CEO Tapio Pajuharju and CFO Ari Vesterinen will host the event. The webcast can be followed at https://harvia.videosync.fi/2021-q3-results/register. You can also participate in the conference by calling: Finland: +358 981 710 310 Sweden: +46 856 642 651 UK: +44 333 300 0804 US: +1 631 913 1422 PIN: 38829315# A recording of the webcast will be available later...

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the third quarter will be released after the close of market on Wednesday, November 10, 2021. About Histogen Inc. Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary,...